Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 10/20 | 0.54 |
| ▸ | ITGA2B | P08514 | 7/20 | 0.54 |
| ▸ | ITGAV | P06756 | 3/20 | 0.49 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.49 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.49 |
| ▸ | ITGA5 | P08648 | 1/20 | 0.49 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.49 |
| ▸ | ITGB5 | P18084 | 1/20 | 0.48 |
| ▸ | CTSG | P08311 | 1/20 | 0.48 |
| ▸ | MC4R | P32245 | 6/20 | 0.48 |
| ▸ | MC5R | P33032 | 6/20 | 0.48 |
| ▸ | MC3R | P41968 | 6/20 | 0.48 |
| ▸ | MC1R | Q01726 | 6/20 | 0.48 |
| ▸ | KDM4A | O75164 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29393726 | 0.94 | ITGB3 (0.59) | ITGB3ITGA2BITGAVCACNA1BCXCR4 | |
| SCHEMBL16301538 | 0.93 | ITGB3 (0.55) | ITGB3ITGA2BITGAVCACNA1BITGB1 | |
| SCHEMBL19412647 | 0.92 | ITGB3 (0.54) | ITGB3ITGA2BITGAVCACNA1BITGB1 | |
| SCHEMBL16135323 | 0.92 | ITGB3 (0.54) | ITGB3ITGA2BITGAVCACNA1BITGB1 | |
| SCHEMBL15160074 | 0.92 | ITGB3 (0.54) | ITGB3ITGA2BITGAVCACNA1BITGB1 | |
| SCHEMBL24454392 | 0.92 | ITGB3 (0.56) | ITGB3ITGA2BITGAVCACNA1BITGB1 | |
| SCHEMBL19018807 | 0.92 | ITGB3 (0.56) | ITGB3ITGA2BITGAVCACNA1BITGB1 | |
| SCHEMBL15308347 | 0.92 | ITGB3 (0.56) | ITGB3ITGA2BITGAVCACNA1BITGB1 | |
| SCHEMBL23839922 | 0.92 | ITGB3 (0.56) | ITGB3ITGA2BITGAVCACNA1BITGB1 | |
| SCHEMBL7746029 | 0.92 | ITGB3 (0.56) | ITGB3ITGA2BITGAVCACNA1BITGB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9439858-B2 | Temperature sensitive liposome including cationic lipid and use thereof | SAMSUNG ELECTRONICS CO., LTD. (KR) | 2016-09-13 | — | — | US | disclosed |
| US-20140294932-A1 | TEMPERATURE SENSITIVE LIPOSOME INCLUDING CATIONIC LIPID AND USE THEREOF | SAMSUNG ELECTRONICS CO., LTD. (KR) | 2014-10-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140294932-A1 | TEMPERATURE SENSITIVE LIPOSOME INCLUDING CATIONIC LIPID AND USE THEREOF | LIPA, LIPE, LPXN | ITGB3 2831/4885ITGA2B 2471/4885ITGAV 1647/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.